As expected, most tumors were scored as luminal A or B. The primary tumor/remote recurrences prior to CDK4/6 therapy start, exhibited a similar frequency of luminal A and B subtypes as observed in the pretreatment metastatic setting (Fig. 5a). Here, CDK4 is linked to neoplasm.